Other investigated SNPs in CALB2, E2F2, and NRF1 genes were not associated with survival or response to cisplatin-based chemotherapy, even though we have previously shown that they could contribute to the interindividual variability observed for serum calretinin concentration in MM patients or asbestos-exposed subjects [36], suggesting that the genetic variability in these genes does not play an important role as a prognostic or predictive biomarker in MM. This evidence concerns the gene NRF1 and Miyoshi myopathy.